Form 4 for TGTX TG THERAPEUTICS, INC.
Accepted 2025-01-30 00:00:00 ET · period of report 2025-01-29 · accession 0001437749-25-002292 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-30 | 2025-01-29 | TGTX | WEISS MICHAEL S | CEO, Dir | A - Grant | $0.00 | +750.0K | 13.82M | +6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-29 | A | A | 750,000 | $0.00 | 13,824,929 | D | — | — | (F1) Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period. (F2) Includes shares of restricted Common Stock, which vest over various time periods. |